Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Free Cash Flow (2020 - 2025)

Bioventus' Free Cash Flow history spans 6 years, with the latest figure at $39.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 115.48% year-over-year to $39.7 million; the TTM value through Dec 2025 reached $74.4 million, up 96.97%, while the annual FY2025 figure was $74.4 million, 96.97% up from the prior year.
  • Free Cash Flow reached $39.7 million in Q4 2025 per BVS's latest filing, up from $29.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $39.7 million in Q4 2025 to a low of -$21.1 million in Q2 2022.
  • Average Free Cash Flow over 5 years is $6.7 million, with a median of $8.6 million recorded in 2021.
  • The largest YoY upside for Free Cash Flow was 354.1% in 2023 against a maximum downside of 539.23% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at $17.0 million in 2021, then plummeted by 64.13% to $6.1 million in 2022, then surged by 127.84% to $13.9 million in 2023, then surged by 32.71% to $18.4 million in 2024, then surged by 115.48% to $39.7 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Free Cash Flow are $39.7 million (Q4 2025), $29.6 million (Q3 2025), and $25.3 million (Q2 2025).